La bourse est fermée
CAC 40
7 015,10 -124,15 (-1,74 %) Euro Stoxx 50
4 130,62 -76,52 (-1,82 %) Dow Jones
32 237,53 +132,28 (+0,41 %) EUR/USD
1,0763 -0,0073 (-0,68 %) Gold future
1 981,00 -14,90 (-0,75 %) Bitcoin EUR
25 618,72 -28,51 (-0,11 %)
Merck & Co., Inc. (MRK.PA)
Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
À la clôture : 03:23PM CEST
| Clôture précédente | 96,40 |
| Ouverture | 95,50 |
| Offre | S.O. x S.O. |
| Vente | S.O. x S.O. |
| Var. jour | 95,40 - 96,40 |
| Sur 52 semaines | 72,50 - 109,00 |
| Volume | |
| Volume moyen | 442 |
| Cap. boursière | 244,72B |
| Bêta (mensuel sur 5 ans) | 0,35 |
| Rapport P/E (sur 12 mois) | 18,36 |
| BPA (sur 12 mois) | 5,25 |
| Date de bénéfices | 27 avr. 2023 |
| Dividende et rendement à terme | 2,76 (2,86 %) |
| Date ex-dividende | 14 mars 2023 |
| Objectif sur 1 an | S.O. |
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
- ACCESSWIRE
Our Partnerships Help Make Vaccines Accessible Worldwide
Providing vaccines to some of the hardest-to-reach places around the world
© 2023 Yahoo. Tous droits réservés.
